

# Lung decortication in phase III pleural empyema by video-assisted thoracoscopic surgery (VATS)—results of a learning curve study

Martin Reichert<sup>1</sup>, Bernd Pösentrup<sup>1</sup>, Andreas Hecker<sup>1</sup>, Winfried Padberg<sup>1</sup>, Johannes Bodner<sup>2,3</sup>

<sup>1</sup>Department of General, Visceral, Thoracic, Transplant and Pediatric Surgery, University Hospital of Giessen, Giessen, Germany; <sup>2</sup>Department of Thoracic Surgery, Klinikum Bogenhausen, Munich, Germany; <sup>3</sup>Department of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, Innsbruck, Austria

*Contributions:* (I) Conception and design: M Reichert, J Bodner; (II) Administrative support: A Hecker, W Padberg; (III) Provision of study materials or patients: W Padberg, J Bodner; (IV) Collection and assembly of data: M Reichert, B Pösentrup; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*Correspondence to:* Martin Reichert, MD. Department of General, Visceral, Thoracic, Transplant and Pediatric Surgery, University Hospital of Giessen, Rudolf-Buchheim Strasse 7, 35392 Giessen, Germany. Email: martin.reichert@chiru.med.uni-giessen.de.

**Background:** Pleural empyema (PE) is a devastating disease with a high morbidity and mortality. According to the American Thoracic Society it is graduated into three phases and surgery is indicated in intermediate phase II and organized phase III. In the latter, open decortication of the lung via thoracotomy is the gold standard whereas the evidence for feasibility and safety of a minimally-invasive video-assisted thoracoscopic approach is still poor.

**Methods:** Retrospective single-center analysis of patients undergoing surgery for phase III PE from 02/2011 to 03/2015 [n=138, including n=130 VATS approach (n=3 of them with bilateral disease) and n=8 open approach]. The learning curve was assessed by grouping those 127 patients with unilateral disease who underwent a video-assisted thoracoscopic approach into two groups: VATS-1 (03/2011 to 06/2012, n=43) and VATS-2 (06/2012 to 03/2015, n=84).

**Results:** ASA-scores (P=0.0279) and rate of pre-operative drainage therapy (P=0.0534) were higher in VATS-2 patients. Operating times were longer in VATS-1 (P=0.0308), intra-operative complication as well as conversion to open surgery rates did both not differ. Rates of post-operative vasoconstrictive therapy (P=0.0191) and prolonged mechanical ventilation (P=0.0560) were both higher in VATS-2, however, post-operative length of stay (LOS) at intensive care unit, overall post-operative LOS and post-operative complication rate were similar in both groups.

**Conclusions:** Video-assisted thoracoscopic surgery is feasible for evacuation and decortication in late phase III PE. A learning curve of approximately 40 cases is sufficient to gain procedure-specific surgical skills and thus reduce the operating times sufficiently.

**Keywords:** Video-assisted thoracoscopic surgery (VATS); learning curve; pleural empyema (PE); lung decortication

Submitted May 01, 2018. Accepted for publication Jun 06, 2018.

doi: 10.21037/jtd.2018.06.72

View this article at: <http://dx.doi.org/10.21037/jtd.2018.06.72>

## Introduction

Pleural empyema (PE) is an infectious condition of the pleural cavity (1). The most frequent cause of PE is pneumonia, when a pre-existing parapneumonic effusion gets superinfected by bacteria, often due to perforation

of a subpleural pulmonary abscess (2,3). Other common causes are previous thoracic surgery or other invasive thoracic interventions, esophageal diseases, trauma, sub-diaphragmatic infections and sepsis (3,4). PE itself is associated with high morbidity and mortality rates

independently from the underlying disease (4). According to the American Thoracic Society (ATS) PE is classified into three phases: the early exudative (phase I), the intermediate fibroproliferative (phase II) and the late organized phase III (1). If therapy is insufficient the earlier phase of PE merges into the next one and the disease gets more complicated (1,3). Therapy is stage dependent and should focus on controlling the infectious focus (i.e., antibiotics), evacuation of fluid and pus collections (needle aspiration, chest tube insertion or surgery), re-expansion of the lung and re-establishment of the physiologic respiratory chest mobility (degradation of fibrinous septa and removal of fibrotic capsules from the lung's surface, the diaphragm, mediastinum and chest wall either by fibrinolytic agents or by surgery) (1,5).

In organized phase III empyema conventional open surgery (COS) via thoracotomy has remained the most established, gold standard approach for decortication. So far, only little experience exists on decortication in late phase PE via a minimally-invasive video-assisted thoracoscopic surgery (VATS) approach (5,6). However, those few so far published retrospective case series suggest principal feasibility and safety of VATS for pulmonary decortication (5,6).

We herein report an institutional experience with the VATS approach for lung decortications in organized phase III PE with a particular focus on the learning curve.

## Methods

At Department of General, Visceral, Transplant and Thoracic Surgery at Giessen University Hospital a VATS-program for more complex thoracic surgical procedures was started in 02/2011. Initially, all complex VATS-procedures (anatomic lung resections, mediastinal tumor resections, decortications in phase III PE) were taken care of by one single experienced senior thoracic surgeon either as the performing surgeon or the teaching assistant.

Only patients with documented ATS-phase III PE with a restrictive pleural scar tissue/fibrous cortex overlying and constraining the visceral pleura were included in this retrospective study. Patients were treated by the institutional standard of care. Patient data were retrospectively analyzed from the prospectively maintained institutional database.

In order to analyze the learning curve of minimally-invasive VATS decortication in organized phase III PE in a cohort as homogenous as possible, patients with bilateral PE and patients primarily conducted to COS for phase III PE

were excluded. Conversions from an initial VATS approach to COS were classified as intra-operative complications and the respective patients were excluded from further outcome analysis. Recurrent disease indicating a redo-operation was classified as post-operative complication and the respective re-VATS or re-COS procedures were not included into the outcome analysis. For assessing the learning curve the cohort of patients was divided into two groups based on operation date [VATS-1: from 03/2011 to 06/2012, n=43 (33.9%) and VATS-2: from 06/2012 to 03/2015, n=84 (66.1%)].

The retrospective acquisition of data was formally approved by the local ethics committee of the medical faculty, Justus-Liebig-University of Giessen, Germany (AZ 114/14 and AZ 242/13). As this is a retrospective patient data analysis, all patients were treated by the present local standard of care.

## Operation technique

Patients were placed in lateral decubitus position and underwent general anesthesia with a double-lumen endotracheal tube for selective single-lung ventilation. An anterior VATS-approach with a 30 degree camera without rib-spreading was used for minimally-invasive empyema evacuation and lung decortication. The thoracocenteses were positioned according to the expansion of the PE based on the patients' pre-operative computed tomography scans. Strict focus was put on initially entering the pleural cavity at an area, where the lung was in direct contact to the chest wall preferably without any empyema lying in between. In most cases the first thoracocentesis was placed in the area of the fourth intercostal space, anterior axillary line; initially in a uniportal approach the lung was gradually mobilized by taking down its adhesions to the chest wall. Dissection was performed mainly bluntly using an endo-Kittner or the cautery hook as a dissector. Once the lung was freed anteriorly all the way down to the diaphragm, two additional basal thoracocenteses were placed to continue the operation in a three port technique. The anterobasal thoracocentesis was used as the camera port. The dissection/lung decortication was processed laterodorsally by peeling the lung's visceral pleura off the fibrous cortex encapsulating the empyema. Thereby care was taken to keep the empyema sac, separating the lung from and surrounding the fluid empyema components, intact. This step was usually facilitated by partial or complete ventilation of the lung via the double-lumen endotracheal tube. After complete mobilization of the lung, empyemectomy was

performed by dissecting the corresponding parts of the empyema capsule off the diaphragm, the chest wall and the (mainly posterior) mediastinum. However, the fibrotic capsule no seldom ruptured during this maneuver—or even earlier—and the leaking liquid empyema components were controlled with a sucker.

At the end of the procedure 1–3 chest tubes were placed and negative pressure was usually applied for at least 2 days and/or until chest X-ray confirmed complete (re-) expansion of the lung. Chest tubes were removed consecutively as soon as air leakage had stopped and/or fluid collection was below 300 mL per day.

### Statistical analysis

Statistical analysis was performed using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California USA, www.graphpad.com. Normally distribution was tested by Shapiro-Wilk test. Two-tailed Mann-Whitney U-test or two-tailed, un-paired Student's T test was used for two-group comparisons of non-parametric or normally distributed data, respectively. Normally distributed data are denoted within the tables. Fisher's exact or Pearson's  $\chi^2$  test was applied for comparisons of categorical data in cross-tabulation.

P values <0.05 were considered to indicate statistical significance. Data are given in mean  $\pm$  SEM as well as in median (range).

### Results

Between 02/2011 and 03/2015 one-hundred-thirty-eight patients were conducted to surgery for late organized phase III PE. Within those, 3 patients had bilateral disease and 8 patients were primarily treated by COS. The remaining 127 (94.1%) patients conducted to minimally-invasive surgical (VATS-approach) empyema evacuation and lung decortication were included into this study.

In 5 patients the initially intended VATS approach was converted to COS and the respective patients were excluded from further outcome analysis. In 8 patients 10 redo-interventions for recurrent disease were performed after initial VATS decortications and those 10 respective redo-procedures were classified as post-operative complications and not included into this primary outcome analysis.

Although patient characteristics within both the VATS-1 and VATS-2 group were widely balanced, male gender was over-represented among patients from VATS-2 and patients from VATS-2 pre-operatively were more multi-morbid reflected by a significantly higher ASA- (American society of anesthesiologists' classification of physical health) score. By tendency more (P=0.0534) patients from VATS-2 (n=37) were treated by pre-operative drainage therapy, indicating a prolonged medical treatment prior to and a delay of surgery (Table 1). However, no differences were observed in the length of pre-operative hospital stay between both groups

**Table 1** Patient characteristics

Variable	VATS-1	VATS-2	P value
Gender (n patients)			0.0117
Male	30 (69.8%)	75 (89.3%)	
Female	13 (30.2%)	9 (10.7%)	
Age (years)	61.9 $\pm$ 12.9; 63.0 (range, 27.0–86.0)	62.3 $\pm$ 17.0; 65.0 (range, 13.0–88.0)	0.5175
BMI (kg/m <sup>2</sup> )	25.3 $\pm$ 5.2; 24.5 (range, 17.3–37.1)	26.3 $\pm$ 4.6; 26.3 (range, 14.2–39.9)	0.1226
Chronic diseases (n patients)			
Pulmonary	22 (51.2%)	37 (44.0%)	0.4592
COPD	8 (18.6%)	11 (13.1%)	0.4378
Emphysema	2 (4.7%)	1 (1.2%)	0.2645
Cardio-vascular	23 (53.5%)	58 (69.0%)	0.1181
Arterial hypertension	15 (34.9%)	43 (51.2%)	0.0927
Coronary arterial disease	5 (11.6%)	21 (25.0%)	0.1039

**Table 1** (continued)

Table 1 (continued)

Variable	VATS-1	VATS-2	P value
Diabetes mellitus	4 (9.3%)	18 (21.4%)	0.1356
Oncologic	13 (30.2%)	17 (20.2%)	0.2699
Neurologic	6 (14.0%)	23 (27.4%)	0.1181
Gastro-intestinal	9 (20.9%)	27 (32.1%)	0.2162
Nephrologic	3 (7.0%)	16 (19.0%)	0.1127
Abuse (n patients)			
Nicotin	7 (16.3%)	12 (14.3%)	0.7959
Alcohol	2 (4.7%)	5 (6.0%)	1
Drugs (i.v.)	0	2 (2.4%)	0.5686
Previous thoracic surgery (n patients)*	7 (16.3%)	21 (25.0%)	0.366
ASA (n patients)	2.6±0.6; 3 (range, 1–4)	2.9±0.6; 3 (range, 1–4)	0.0279
1	1 (2.3%)	1 (1.2%)	
2	16 (37.2%)	18 (21.4%)	
3	24 (55.8%)	55 (65.5%)	
4	2 (4.7%)	10 (11.9%)	
Side (n patients)			0.0386
Right	30 (69.8%)	42 (50.0%)	
Left	13 (30.2%)	42 (50.0%)	
Etiology (n patients)			0.0854
Parapneumonic	17 (39.5%)	41 (48.8%)	
Pneumothorax	2 (4.7%)	1 (1.2%)	
Post-interventional			
Thoracic operation	3 (7.0%)	15 (17.9%)	
Thoracic drainage	4 (9.3%)	2 (2.4%)	
Post-traumatic	3 (7.0%)	3 (3.6%)	
Cancer/paraneoplastic	6 (14.0%)	4 (4.8%)	
Chronic pleural fluid collection	8 (18.6%)	18 (21.4%)	
Pre-operative drainage therapy (n patients)	11 (25.6%)	37 (44.0%)	0.0534
Duration (d)	9.8±6.0; 10 (range, 1.0–22.0)	11.8±13.8; 8.0 (range, 1.0–73.0)	0.7734
Pre-operative oral temperature >38 °C (n patients) <sup>#</sup>	11 (27.5%)	29 (35.8%)	0.4155
Pre-operative oral temperature (°C) <sup>§</sup>	37.6±1.0; 37.7 (range, 36.0–39.8)	37.6±0.9; 37.5 (range, 35.8–40.3)	0.8699

\*, previous thoracic surgery in the VATS-1 group (7 patients): VATS (n=5), aortocoronary bypass surgery (n=2). Previous thoracic surgery in the VATS-2 group (21 patients: 3 patients underwent 2 thoracic surgical procedures previously): thoracotomy (n=4), VATS (n=13), aortocoronary bypass surgery (n=7). <sup>#</sup>, not available retrospectively in 3 patients of both the VATS-1 and the VATS-2 group. <sup>§</sup>, normally distributed data. BMI, body mass index; COPD, chronic obstructive pulmonary disease; ASA, American Society of Anesthesiologists' classification of physical health.

(Table 2).

Operating times were significantly longer ( $P=0.0308$ ) among the first third of patients (VATS-1) compared to the following two thirds (VATS-2). Nevertheless, no differences were seen in the rate of intra-operative complications or conversions to open surgery as well as the intra-operative blood loss (Tables 2,3).

Both the overall length of stay (LOS) at intensive care unit (ICU) as well as the post-operative LOS at ICU was similar between both groups (Table 2). However, rates of prolonged post-operative mechanical ventilation as well as catecholamine therapy were higher in patients from VATS-2. The rate of delayed ( $>10$  d) post-operative chest tube removal indicating a prolonged post-operative air leakage and/or a prolonged post-operative high chest tube output was slightly ( $P=0.0702$ ) higher in patients from VATS-2. No differences were observed in post-operative complication rates and post-operative in-hospital LOS among both groups (Tables 2,3).

## Discussion

Complete decortication, i.e., removal of all fibrotic tissue constricting the lung is of utmost importance for the success of surgical therapy in phase III PE. Any remaining cortex on the lung's surface preventing its complete re-expansion and thus leaving an empty space within the pleural cavity leads to recurrent pleural effusion which is of high risk for getting re-infected; mainly when the—most often—underlying pneumonia is usually not fully recovered at time of surgery.

Lung decortication is a challenging and time-consuming procedure. Meticulous dissection is mandatory in order to peel the sticking fibrotic cortex off the visceral pleura without causing too many lesions consequently leading to prolonged air leaks. The most established surgical approach for lung decortication in late phase PE is COS and the minimally-invasive VATS approach has been evaluated quite delayed (when compared to other complex thoracic procedures like anatomic lung resections) for this particular procedure.

The feasibility of evacuation and decortication in phase III PE via a VATS approach initially was suggested in various retrospective analysis: their validity was limited by rather small and mostly inhomogeneous cohorts mixing up both phase II and III PE patients (5,8). However, those series suggested that the benefits [with regard to post-operative pain, post-operative complication rate, LOS, pulmonary function, quality of life (9-13)] of a VATS over a

COS approach known in oncologic thoracic surgery come to effect also in empyema surgery (5,14-17). Thus, in its recent expert consensus statement the European Association for Cardio-Thoracic Surgery (EACTS) has recommended a primary VATS-approach for the surgical management even for organized phase III PE (5).

Overall, reported post-operative morbidity, mortality and re-intervention rates (up to 25.1%, 7.6% and 23.8%, respectively) of VATS decortications in phase III PE are rather high (5) and a limited experience in thoracic surgery is reported to be one risk factor for intra-operative conversion to COS as well as for treatment failure after surgery (5,8). Thus, the surgeons' experience and technical skills seem to be a major factor influencing the outcome in VATS empyema surgery. For VATS pulmonary lobectomies a number of 30 to 50 procedures was quoted as the required learning curve numbers of an averaged talented trainee and 20 cases per year were recommended to preserve the technical skills constantly (18-21). Compared to lobectomies for early (I) stage non-small cell lung cancer (NSCLC), thoracic surgery in chronic inflammatory/infectious conditions is technically even more challenging due to severe adhesions and fibrotic changes, neovascularization and lymph node reactions (22-25). Visualization and anatomic orientation are impaired, which bears the risk for significant bleeding by injuring hilar structures during mobilization of the lung. This study aimed to determine a realistic learning curve volume for VATS decortications in phase III PE by evaluating operative time, peri-operative complication and morbidity rates. Hypothesizing the learning curve to be at least the same or even higher than known in minimally-invasive anatomic lung resections (18-21), outcomes of the first, assumed "learning curve" third of patients ( $n=43$ ) were compared to those of the second two thirds of patients ( $n=84$ ). Severity of disease was similar between both groups although in VATS-2 patients both higher pre-operative CRP-values and pre-operative body temperature indicated severer inflammatory reactions and a longer pre-operative drainage therapy indicated a potentially delayed decision for surgery (Tables 1,3) (14,26,27). However, operative times as the most relevant outcome parameter for the learning curve was significantly longer among VATS-1 compared to VATS-2 patients. Post-operative LOS at ICU, chest tube duration and post-operative overall LOS were chosen as secondary outcome parameters in this study. Interestingly, despite shorter operative times in VATS-2 and a similar LOS at ICU among both groups, both the rates of

Table 2 Peri-operative outcome

Variable	VATS-1	VATS-2	P value
Operation time (min)	170.1±73.6; 155.0 (range, 41.0–378.0)	141.6±61.1; 138.0 (range, 43.0–385.0)	0.0308
Hospital stay (d)			
Total	22.2±14.2; 15.0 (range, 9.0–57.0)	30.4±35.3; 20.0 (range, 5.0–232.0)	0.5746
Pre-operative*	8.6±8.9; 5.0 (range, 2.0–45.0)	9.9±12.8; 5.0 (range, 2.0–75.0)	0.608
PO	13.9±10.0; 9.0 (range, 4.0–45.0)	20.3±30.7; 10.0 (range, 3.0–230.0)	0.7384
Stay on ICU (h)			
Total	124.2±231.2; 25.0 (range, 0.0–1,339.0)	410.3±897.5; 42.9 (range, 0.0–5,534.0)	0.1104
PO	99.3±190.2; 25.0 (range, 0.0–1,079.0)	306.3±763.2; 41.9 (range, 0.0–5,517.0)	0.1471
PO mechanical ventilation (n patients) <sup>ε</sup>	9 (22.0%)	24 (29.6%)	0.3978
Duration (h)	35.5±83.5; 8.4 (range, 1.65–260.8)	469.8±1,148.0; 128.1 (range, 3.1–5,517.0)	0.0034
Prolonged (>120 h) (n patients) <sup>ε</sup>	1 (2.4%)	12 (14.8%)	0.056
Catecholamine on ICU			
Total (n patients)	4 (9.8%)	29 (35.8%)	0.0023
0–24 h PO			
Patients (n)	4 (9.8%)	29 (35.8%)	0.0023
Volume (µg/kgbw/min)	0.20±0.24; 0.10 (range, 0.06–0.56)	0.13±0.04; 0.08 (range, 0.003–1.25)	0.3075
24–48 h PO			
Patients (n)	3 (7.3%)	21 (25.9%)	0.0158
Volume (µg/kgbw/min)	0.04±0.02; 0.03 (range, 0.02–0.06)	0.21±0.55; 0.04 (range, 0.002–2.50)	0.8614
48–72 PO			
Patients (n)	1 (2.4%)	14 (17.3%)	0.0191
Volume (µg/kgbw/min)	0.05	0.23±0.53; 0.03 (range, 0.001–2.00)	Small sample
Additional surgical procedures (n patients)			
Pulmonary (wedge/major) resection	4 (9.8%)	4 (4.9%)	0.44
Lymph node assessment	2 (4.9%)	1 (1.2%)	0.2611
Number of thoracenteses (n patients)			0.0344
1	3 (7.3%)	0	
2	9 (22.0%)	14 (17.3%)	
3	29 (70.7%)	67 (82.7%)	
IO blood loss (mL)	490.7±423.2; 400.0 (range, 40.0–2,000.0)	545.4±561.0; 300.0 (range, 0.0–2,600.0)	0.9027
Blood transfusion			
Total (n patients)	14 (34.1%)	37 (45.7%)	0.2485
IO (n patients)	13 (31.7%)	23 (28.4%)	0.8338
IO (No. of EC)	2.0±1.3; 2 (range, 1–6)	2.4±2.6; 2 (range, 1–13)	0.6277
PO (n patients)	5 (12.2%)	30 (37.0%)	0.0054
PO (No. of EC)	2.8±2.2; 2 (range, 1–6)	4.3±3.1; 4 (range, 1–14)	0.293

\*, including those patients (2 patients in VATS-1 and 3 patients in VATS-2) underwent conversion to open surgery; <sup>ε</sup>, mechanical ventilation of patients not being extubated after surgery, acute respiratory insufficiency and re-intubation were classified as complications. PO, post-operative; ICU, intensive care unit; BW, body weight; IO, intra-operative; EC, erythrocyte concentrate.

**Table 3** Peri-operative complications and drainage management

Variable	VATS-1	VATS-2	P value
IO complications (n)			
Total*	6 (14.0%)	11 (13.1%)	1
Conversions <sup>¶</sup>	2 (4.7%)	3 (3.6%)	1
Total PO complications (n patients)			0.7037
n (%)	21 (51.2%)	38 (46.9%)	
Grade I <sup>€</sup>	3	5	
Grade II <sup>€</sup>			
Bleeding	2	5	
Pneumonia	2	6	
GI infection	1	1	
TAA	0	2	
Prolonged PO chest drainage therapy $\geq 10$ d	5	18	
Others	0	5	
Grade IIIa <sup>€</sup>			
Re-drainage	3	6	
Bronchoscopy	2	1	
Others	0	3	
Grade IIIb <sup>€</sup>			
Recurrent empyema	3	5 <sup>§</sup>	
Others <sup>¶</sup>	4	4	
Grade IVa <sup>€</sup>			
Acute respiratory insufficiency	1	1	
Chronic respiratory insufficiency	1	12	
Acute renal failure	2	2	
Others	0	3	
Mortality (n patients) <sup>§</sup>	2 (4.9%)	9 (11.1%)	0.3314
No. of IO placed chest tubes (n patients)			<0.0001
1	10 (24.4%)	12 (14.8%)	
2	11 (26.8%)	66 (81.5%)	
3	20 (48.8%)	3 (3.7%)	
PO chest tube duration (d) <sup>¶</sup>	6.15 $\pm$ 3.02; 6.0 (range, 2.0–16.0)	7.01 $\pm$ 4.45; 5.0 (range, 2.0–22.0)	0.7035
$\geq 7$ d (n patients) <sup>€</sup>	14 (34.1%)	30 (37.0%)	0.8428
$>10$ d (n patients) <sup>€</sup>	3 (7.3%)	17 (21.0%)	0.0702
Blood leucocytes			
Elevated pre-operative (n patients)*	30 (69.8%)	51 (60.7%)	0.337

Table 3 (continued)

Table 3 (continued)

Variable	VATS-1	VATS-2	P value
Highest value pre-operative (giga/L)*	15.23±8.01; 14.0 (3.2–38.6)	14.50±8.91; 11.9 (range, 4.6–54.2)	0.3131
Elevated POD 3–6 (n patients) <sup>#</sup>	9 (22.0%)	20 (24.7%)	0.8227
Highest value POD 3–6 (giga/L) <sup>#</sup>	8.41±3.48; 7.8 (2.2–19.6)	9.06±6.75; 8.0 (range, 2.9–61.5)	0.9418
Elevated at discharge (n patients)	16 (39.0%)	23 (28.4%)	0.3043
Value at discharge (giga/L)	10.35±4.52; 9.6 (3.3–25.0)	9.42±5.29; 8.4 (range, 2.9–42.1)	0.0833
C-reactive protein			
>10 mg/L pre-operative (n patients)*	38 (88.4%)	83 (98.8%)	0.0168
Highest value pre-operative (mg/L)*	162.2±152.0; 110.0 (range, 5.3–532.2)	156.6±120.1; 134.0 (range, 0.6–485.5)	0.8344
Highest value POD 3–6 (mg/L) <sup>#</sup>	89.94±47.24; 84.6 (range, 5.9–263.3)	102.1±48.29; 98.8 (range, 0.5–260.6)	0.1272
Value at discharge (mg/L) <sup>^</sup>	81.68±72.81; 81.3 (range, 0.5–424.9)	72.24±50.68; 68.3 (range, 0.5–212.5)	0.5972

\*, including those patients underwent conversion to open surgery. <sup>†</sup>, the two conversions in the VATS-1 group were due to technical reasons in 1 case and due to bleeding in 1 case. The three conversions in VATS-2 were due to technical reasons in 2 cases and due to bleeding in 1 case. <sup>€</sup> according to the Dindo-Clavien classification of surgical complications (7). <sup>§</sup>, 5 patients from VATS-2 suffered from 7 recurrences after surgery. <sup>‡</sup>, beside (operative) redo-procedures for empyema recurrences, 3 patients in VATS-1 and 4 patients in VATS-2 underwent 4 operative redo-procedures in each group [including re-VATS for organized hemothorax (n=1) and malignant pleural effusion (n=2) as well as re-thoracotomy for persistent air leak (n=1) in VATS-1 and re-VATS for organized hemothorax (n=2) and re-thoracotomy for bleeding (n=1) in VATS-2]. <sup>§</sup>, 30-day and in-hospital mortality [according to grade V complications regarding the Clavien-Dindo classification of surgical complications (7)] as well as septic multi-organ failure [according grade IV complications regarding the Clavien-Dindo classification of surgical complications (7)] leading to death. <sup>¶</sup>, means the duration of the primarily (intraoperative) placed chest tube/s. Chest tube re-insertion et cetera was classified as a complication. One patient of the VATS-1 group died before chest tube removal and one patient from VATS-2 was discharged with a chest tube and a Heimlich valve. <sup>€</sup>, prolonged chest tube duration was considered to indicate persistent air leak (prolonged parenchyma fistula) and/or high fluid losses. <sup>#</sup>, not available retrospectively in 2 patients of the VATS-1 and 4 patients of the VATS-2 group. <sup>^</sup>, not available retrospectively in 2 patients of the VATS-2 group. IO, intra-operative; PO, post-operative; GI, gastro-intestinal; TAA, tachyarrhythmia. POD, post-operative day.

prolonged post-operative mechanical ventilation and of prolonged vasoconstrictive therapy were higher in VATS-2. This may be explained by the impaired physical status and a higher peri-operative risk of the respective patients reflected by significantly higher pre-operative ASA-scores in VATS-2 (28). The constantly rising ASA-score over the study period might indicate that with growing surgical experience even severer cases and sicker patients were operated on.

The LOS at ICU as well as the duration of chest tube insertion are both parameters significantly influencing the overall post-operative LOS (29). A prolonged air leak and/or a prolonged high volume output are frequent post-operative complications inducing a delayed (>10 days) chest tube removal (29–31). The rate of prolonged chest tube duration was slightly higher in VATS-2 (P=0.0702), which might, however, be based on the fact that fewer tubes were inserted in patients of this subgroup; thus, delayed removal eventually could have been prevented by a more extensive

(3 vs. 2 tubes) initial drainage of the pleural cavity at the end of operation, thereby facilitating an immediate complete re-expansion of the lung. The higher rate of patients who underwent mechanically over-pressure ventilation post-operatively may explain the higher rate of prolonged air leaks in VATS-2.

In conclusion, a VATS approach for empyema evacuation and lung decortication in phase III PE has shown to be feasible and safe with an acceptable rate of peri-operative morbidity in this study. A significant reduction of operative times between the two subgroups suggests a learning curve volume of approximately 40 cases as being sufficient in order to develop relevant procedure specific surgical skills and experience.

### Acknowledgements

None.



## Footnote

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

*Ethical Statement:* The retrospective acquisition of data was formally approved by the local ethics committee of the medical faculty, Justus-Liebig-University of Giessen, Germany (AZ 114/14 and AZ 242/13).

## References

- Andrews NC, Parker EF, Shaw RR, et al. Management of non tuberculous empyema: a statement of the subcommittee on surgery. *Am Rev Respir Dis* 1962;85:935-6.
- Pothula V, Krellenstein DJ. Early aggressive surgical management of parapneumonic empyemas. *Chest* 1994;105:832-6.
- Reichert M, Hecker M, Witte B, et al. Stage-directed therapy of pleural empyema. *Langenbecks Arch Surg* 2017;402:15-26.
- Hamm H, Light RW. Parapneumonic effusion and empyema. *Eur Respir J* 1997;10:1150-6.
- Scarci M, Abah U, Solli P, et al. EACTS expert consensus statement for surgical management of pleural empyema. *Eur J Cardiothorac Surg* 2015;48:642-53.
- Reichert M, Posentrup B, Hecker A, et al. Thoracotomy versus video-assisted thoracoscopic surgery (VATS) in stage III empyema-an analysis of 217 consecutive patients. *Surg Endosc* 2018;32:2664-75.
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205-13.
- Waller DA, Rengarajan A. Thoracoscopic decortication: a role for video-assisted surgery in chronic postpneumonic pleural empyema. *Ann Thorac Surg* 2001;71:1813-6.
- Whitson BA, Groth SS, Duval SJ, et al. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. *Ann Thorac Surg* 2008;86:2008-16; discussion 2016-8.
- Yan TD, Black D, Bannon PG, et al. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. *J Clin Oncol* 2009;27:2553-62.
- Zhang Z, Zhang Y, Feng H, et al. Is video-assisted thoracic surgery lobectomy better than thoracotomy for early-stage non-small-cell lung cancer? A systematic review and meta-analysis. *Eur J Cardiothorac Surg* 2013;44:407-14.
- Handy JR Jr, Asaph JW, Douville EC, et al. Does video-assisted thoracoscopic lobectomy for lung cancer provide improved functional outcomes compared with open lobectomy? *Eur J Cardiothorac Surg* 2010;37:451-5.
- Demmy TL, Nwogu C. Is video-assisted thoracic surgery lobectomy better? Quality of life considerations. *Ann Thorac Surg* 2008;85:S719-28.
- Chung JH, Lee SH, Kim KT, et al. Optimal timing of thoracoscopic drainage and decortication for empyema. *Ann Thorac Surg* 2014;97:224-9.
- Cardillo G, Carleo F, Carbone L, et al. Chronic postpneumonic pleural empyema: comparative merits of thoracoscopic versus open decortication. *Eur J Cardiothorac Surg* 2009;36:914-8.
- Chan DT, Sihoe AD, Chan S, et al. Surgical treatment for empyema thoracis: is video-assisted thoracic surgery "better" than thoracotomy? *Ann Thorac Surg* 2007;84:225-31.
- Demmy TL, Plante AJ, Nwogu CE, et al. Discharge independence with minimally invasive lobectomy. *Am J Surg* 2004;188:698-702.
- Yan TD, Cao C, D'Amico TA, et al. Video-assisted thoracoscopic surgery lobectomy at 20 years: a consensus statement. *Eur J Cardiothorac Surg* 2014;45:633-9.
- Petersen RH, Hansen HJ. Learning curve associated with VATS lobectomy. *Ann Cardiothorac Surg* 2012;1:47-50.
- Zhao H, Bu L, Yang F, et al. Video-assisted thoracoscopic surgery lobectomy for lung cancer: the learning curve. *World J Surg* 2010;34:2368-72.
- Reichert M, Gohlke AB, Augustin F, et al. Video-assisted thoracoscopic anatomic lung resections in Germany-a nationwide survey. *Langenbecks Arch Surg* 2016;401:877-84.
- Weber A, Stammberger U, Inci I, et al. Thoracoscopic lobectomy for benign disease--a single centre study on 64 cases. *Eur J Cardiothorac Surg* 2001;20:443-8.
- Yim AP, Ko KM, Ma CC, et al. Thoracoscopic lobectomy for benign diseases. *Chest* 1996;109:554-6.
- Chen QK, Chen C, Chen XF, et al. Video-assisted thoracic surgery for pulmonary aspergilloma: a safe and effective procedure. *Ann Thorac Surg* 2014;97:218-23.
- Reichert M, Kerber S, Posentrup B, et al. Anatomic lung resections for benign pulmonary diseases by video-assisted thoracoscopic surgery (VATS). *Langenbecks Arch Surg* 2016;401:867-75.

26. Stefani A, Aramini B, della Casa G, et al. Preoperative predictors of successful surgical treatment in the management of parapneumonic empyema. *Ann Thorac Surg* 2013;96:1812-9.
27. Lardinois D, Gock M, Pezzetta E, et al. Delayed referral and gram-negative organisms increase the conversion thoracotomy rate in patients undergoing video-assisted thoracoscopic surgery for empyema. *Ann Thorac Surg* 2005;79:1851-6.
28. Wolters U, Wolf T, Stutzer H, et al. ASA classification and perioperative variables as predictors of postoperative outcome. *Br J Anaesth* 1996;77:217-22.
29. Liberman M, Muzikansky A, Wright CD, et al. Incidence and risk factors of persistent air leak after major pulmonary resection and use of chemical pleurodesis. *Ann Thorac Surg* 2010;89:891-7; discussion 897-8.
30. Brunelli A, Xiume F, Al Refai M, et al. Air leaks after lobectomy increase the risk of empyema but not of cardiopulmonary complications: a case-matched analysis. *Chest* 2006;130:1150-6.
31. Stolz AJ, Schutzner J, Lischke R, et al. Predictors of prolonged air leak following pulmonary lobectomy. *Eur J Cardiothorac Surg* 2005;27:334-6.

**Cite this article as:** Reichert M, Pösentrup B, Hecker A, Padberg W, Bodner J. Lung decortication in phase III pleural empyema by video-assisted thoracoscopic surgery (VATS)—results of a learning curve study. *J Thorac Dis* 2018;10(7):4311-4320. doi: 10.21037/jtd.2018.06.72